a cell-cycle regulatory protein that Interacts with cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at G1. Its expression is tightly controlled by p53, through which this protein mediates the p53-dependent cell cycle arrest at G1 phase. Note: This description may include information from UniProtKB.
Cellular Component: cyclin-dependent protein kinase holoenzyme complex; cytosol; nucleoplasm; nucleus; perinuclear region of cytoplasm
Molecular Function: cyclin binding; cyclin-dependent protein kinase activating kinase activity; cyclin-dependent protein kinase inhibitor activity; metal ion binding; protein binding; protein complex binding; ubiquitin protein ligase binding
Biological Process: cell cycle arrest; cellular response to amino acid starvation; cellular response to extracellular stimulus; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; G1/S transition of mitotic cell cycle; G2/M transition of mitotic cell cycle; innate immune response; mitotic cell cycle; negative regulation of apoptosis; negative regulation of cell growth; negative regulation of cell proliferation; negative regulation of cyclin-dependent protein kinase activity; negative regulation of phosphorylation; nerve growth factor receptor signaling pathway; organ regeneration; phosphoinositide-mediated signaling; positive regulation of B cell proliferation; positive regulation of fibroblast proliferation; positive regulation of programmed cell death; Ras protein signal transduction; regulation of cyclin-dependent protein kinase activity; regulation of protein import into nucleus, translocation; response to arsenic; response to corticosterone stimulus; response to DNA damage stimulus; response to drug; response to hyperoxia; response to organic nitrogen; response to toxin; response to X-ray
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.